Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Meri Beckwith _2024
Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots
Shots:  Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots  Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data  Meri highlights the importance of multidisciplinary…
May 8, 2024
VIEWPOINTS_Salomé Juethner_2024
Takeda at AAAAI 2024: Salomé Juethner highlights P-IV Results from ENABLE and EMPOWER Studies
Shots:  At the American Academy of Allergy, Asthma, & Immunology (AAAAI), Takeda presented 9 abstracts focusing on health equity and real-world data from P-IV (ENABLE) & (EMPOWER) studies evaluating HAE patients  Salomé Juethner, Senior Medical Director-Head of Rare Genetics at Takeda, in a stimulating conversation with PharmaShots, talks about shares insights from the real-world P-IV…
May 6, 2024
VIEWPOINTS_Angela Cacace_2024
Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots
Shots: Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseases ARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…
April 29, 2024
VIEWPOINTS_Raviv Pryluk_2024
Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace
Shots:   Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma    The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies   Raviv highlights the…
April 23, 2024
VIEWPOINTS_Mo Jain_2024
Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services
Shots:  Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots  Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome  While highlighting Sapient’s…
April 16, 2024
VIEWPOINTS_Neal Shore_2024
Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots
Shots:   At ASCO GU, Bayer presented new data from its Oncology portfolio. The analysis revolved around NUBEQA (darolutamide), which is currently approved in the US in combination with docetaxel for the treatment of mHSPC and nmCRPC in adults   Neal Shore in conversation with PharmaShots initiated the discussion by familiarizing our audience with the ARASENS P-III…
April 10, 2024
VIEWPOINTS_Kari Wong_2024
Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN
Shots:   Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots    The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…
April 8, 2024
VIEWPOINTS_Ofer Gonen_2024
Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots
Shots:  Ofer Gonen, CEO at MediWound, in conversation with PharmaShots, sheds light on recent funding from the US Department of Defence to further develop NexoBrid for the US Army  NexoBrid an FDA-approved enzymatic therapy to treat severe burns is jointly developed by Vericel and received US FDA approval in Dec’22  MediWound secured an additional $6.7M…
April 4, 2024
VIEWPOINTS_Ahsan Arozullah_2024
A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah
Shots:  Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC)  Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…
April 2, 2024
VIEWPOINTS_David Jackson_2024
SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study
Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024
Load more